| Author/Editor | Šega-Jazbec, Saša | |
| Title | Primerjava vpliva terapije z interferonom beta-1a in interferonom beta-1b na potek bolezni, citokine in adhezijske molekule pri bolnikih z recidivno-remitentno multiplo sklerozo | |
| Type | monografija | |
| Place | Ljubljana | |
| Publisher | Univerza v Ljubljani, Medicinska fakulteta | |
| Publication year | 2005 | |
| Volume | str. 92 | |
| Language | slo | |
| Abstract | Background. Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and autoimmune disease of the central nervous system. lt is the most common cause of chronic neurological disability in young adults. There is no drug, which would stop or cure the disease. Immunomodulatory drugs such as recombinant beta interferon (IFN-B) and glatiramer acetate have some influence on the course of the disease. They reduce the number and severity of relapses, they reduce the number of new enhancing MRI lesions and slow down the progression of disability. There are currently three commercial formulations of recombinant IFN-B: Avonex (IFN-(B1a), Rebif (IFNB1a) and Betaferon (IFN-B1b). They differ in dosage and in route and frequency of administration, and consequently most probably in clinical effectiveness. The objectives of the study were to compare the clinical effectiveness and immunomodulatory activity of Avonex (IFN-(B1a), Rebif (IFN-B1a) and Betaferon (IFNB1b) by studying disease course, cytokines levels (IFN-y, IL-4, IL-6, IL-10) and expression of adhesion molecules before and during treatment and to compare responders and nonresponders to treatment. Patients and Methods. Twenty-nine patients with relapsing-remmiting MS were enrolled in the study. Ten patients were treated with Avonex (IFN-B1a), 7 patients with Rebif (IFNB-1a) and 12 patients with Betaferon (IFN-B1b). The influence of therapy on disease course was evaluated by number of relapses, number of steroid treatments and by EDSS. (Abstract truncated at 2000 characters) | |
| Descriptors | MULTIPLE SCLEROSIS INTERFERON-BETA INTERFERON TYPE II INTERLEUKIN-4 INTERLEUKIN-6 INTERLEUKIN-10 INTERCELLULAR ADHESION MOLECULE-1 INTEGRINS ENZYME-LINKED IMMUNOSORBENT ASSAY FLOW CYTOMETRY |